CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
PEG-Introndrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00457418
NCT00457418Phase 1Completed
CompareCT.gov

A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma

Merck Sharp & Dohme LLC·interventional·Posted Apr 6, 2007·Updated Jun 7, 2017

In Brief

A Phase 1 clinical trial evaluating PEG-Intron for Melanoma. Completed, enrolled 32 participants.

Detailed Summary

The purpose of this study is to establish the pharmacokinetics of PEG-Intron, administered at a dose of 6 μg/kg/week for 8 weeks (induction treatment), followed by a dose of 3 μg/kg/week for up to 252 weeks (maintenance treatment), in patients with high risk melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 6, 2007
Enrollment StartFeb 20, 2007
Primary CompletionMay 27, 2008
Study CompletionJul 11, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.2 years ago

Interventions

PEG-Introndrug